Article

The Availability of Advanced Radiation Oncology Technology Within VHA Radiation Oncology Centers

Author and Disclosure Information

 

References

Although BT and SRS are not as widely available within the VHA as other evaluated technologies such as IGRT and IMRT, their availability mirrors a similar limited availability in the community. 10-12 When necessary these services also can be provided for veterans through referral to other VHA or non-VHA centers.

The benefit of charged particle radiotherapy, such as proton beam radiotherapy, is limited to specific cancers. 13 This technology is not widely available in the community or within the VHA. Because of a VHA policy currently in place permitting non-VHA care when needed, veterans who require treatment with charged particle radiotherapy are referred to accredited non-VHA radiation oncology centers when indicated.

Conclusion

In this survey, 92% of the VHA radiation oncology centers are accredited by the American College of Radiology. Further, VHA radiation oncologists respondents reported availability of treatment technologies in line with responses of physicians from community based surveys. The majority of VHA radiation oncologists report access to IMRT, IGRT, CBCT, and SBRT. While BT and SRS are not available onsite at the majority of the 40 VHA radiation oncology centers, this mirrors limited availability and use of these technologies in the community as well.

Acknowledgments
This article was based on a presentation at the ASCO Quality Care Symposium (October 17-18, 2014) in Boston, Massachusetts. Dawson GA, Cheuk AV, Jolly S, et al. Advanced radiation oncology technology within the Veterans Health Administration (VHA). J Clin Oncol. 214;32(suppl 30):52.

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies.

Click here to read the digital edition.

Pages

Recommended Reading

An Atypical Angiomyomatous Hamartoma With Unexplained Hepatosplenomegaly
Federal Practitioner
ASCO Expands Its Role in Cancer Care
Federal Practitioner
Study Points to Risk Factors for Lymphoma
Federal Practitioner
Change in end-of-life cancer care imperative
Federal Practitioner
Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
Federal Practitioner
The Long Legacy of Agent Orange
Federal Practitioner
Guidelines tackle long-term screening, management of myeloma
Federal Practitioner
Phase III trial: VZV protects auto-HCT patients
Federal Practitioner
‘Strong evidence’ links obesity to cancers
Federal Practitioner
Best Practices in Hematology and Oncology (February 2017)
Federal Practitioner